Surface enhanced deep Raman detection of cancer tumour through 71 mm of heterogeneous tissue.

Q1 Pharmacology, Toxicology and Pharmaceutics
Nanotheranostics Pub Date : 2022-03-21 eCollection Date: 2022-01-01 DOI:10.7150/ntno.71510
Priyanka Dey, Alexandra Vaideanu, Sara Mosca, Marzieh Salimi, Benjamin Gardner, Francesca Palombo, Ijeoma Uchegbu, Jeremy Baumberg, Andreas Schatzlein, Pavel Matousek, Nick Stone
{"title":"Surface enhanced deep Raman detection of cancer tumour through 71 mm of heterogeneous tissue.","authors":"Priyanka Dey,&nbsp;Alexandra Vaideanu,&nbsp;Sara Mosca,&nbsp;Marzieh Salimi,&nbsp;Benjamin Gardner,&nbsp;Francesca Palombo,&nbsp;Ijeoma Uchegbu,&nbsp;Jeremy Baumberg,&nbsp;Andreas Schatzlein,&nbsp;Pavel Matousek,&nbsp;Nick Stone","doi":"10.7150/ntno.71510","DOIUrl":null,"url":null,"abstract":"<p><p>Detection of solid tumours through tissue- from depths relevant to humans- has been a significant challenge for biomedical Raman spectroscopy. The combined use of surface enhanced Raman scattering (SERS) imaging agents with deep Raman spectroscopy (DRS), i.e., surface enhanced deep Raman spectroscopy (SEDRS), offer prospects for overcoming such obstacles. In this study, we investigated the maximum detection depth through which the retrieval of SERS signal of a passively targeted biphenyl-4-thiol tagged gold nanoparticle (NP) imaging agent, injected subcutaneously into a mouse bearing breast cancer tumour, was possible. A compact 830 nm set-up with a hand-held probe and the flexibility of switching between offset, transmission and conventional Raman modalities was developed for this study. <i>In vivo</i> injection of the above SERS NP primary dose allowed surface tumour detection, whereas additional post mortem NP booster dose was required for detection of deeply seated tumours through heterogeneous animal tissue (comprising of proteins, fat, bone, organs, blood, and skin). The highest detection depth of 71 mm was probed using transmission, translating into a ~40% increase in detection depth compared to earlier reports. Such improvements in detection depth along with the inherent Raman chemical sensitivity brings SEDRS one step closer to future clinical cancer imaging technology.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":" ","pages":"337-349"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194587/pdf/","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanotheranostics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7150/ntno.71510","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 9

Abstract

Detection of solid tumours through tissue- from depths relevant to humans- has been a significant challenge for biomedical Raman spectroscopy. The combined use of surface enhanced Raman scattering (SERS) imaging agents with deep Raman spectroscopy (DRS), i.e., surface enhanced deep Raman spectroscopy (SEDRS), offer prospects for overcoming such obstacles. In this study, we investigated the maximum detection depth through which the retrieval of SERS signal of a passively targeted biphenyl-4-thiol tagged gold nanoparticle (NP) imaging agent, injected subcutaneously into a mouse bearing breast cancer tumour, was possible. A compact 830 nm set-up with a hand-held probe and the flexibility of switching between offset, transmission and conventional Raman modalities was developed for this study. In vivo injection of the above SERS NP primary dose allowed surface tumour detection, whereas additional post mortem NP booster dose was required for detection of deeply seated tumours through heterogeneous animal tissue (comprising of proteins, fat, bone, organs, blood, and skin). The highest detection depth of 71 mm was probed using transmission, translating into a ~40% increase in detection depth compared to earlier reports. Such improvements in detection depth along with the inherent Raman chemical sensitivity brings SEDRS one step closer to future clinical cancer imaging technology.

Abstract Image

Abstract Image

Abstract Image

表面增强深拉曼检测癌肿瘤通过71毫米的异质组织。
通过组织检测实体肿瘤——从与人类相关的深度——一直是生物医学拉曼光谱的重大挑战。表面增强拉曼散射(SERS)显像剂与深拉曼光谱(DRS)的结合使用,即表面增强深拉曼光谱(SEDRS),为克服这些障碍提供了前景。在这项研究中,我们研究了被动靶向联苯-4-硫醇标记金纳米颗粒(NP)显像剂的最大检测深度,通过该显像剂皮下注射到患有乳腺癌的小鼠体内,可以检索SERS信号。为本研究开发了一种紧凑的830纳米装置,配有手持探头,可灵活地在偏移、传输和传统拉曼模式之间切换。在体内注射上述SERS NP初级剂量可以检测表面肿瘤,而通过异质动物组织(包括蛋白质、脂肪、骨骼、器官、血液和皮肤)检测深层肿瘤则需要额外的死后NP增强剂量。使用透射法探测的最高探测深度为71 mm,与之前的报告相比,探测深度增加了约40%。这种检测深度的提高以及固有的拉曼化学敏感性使SEDRS向未来的临床癌症成像技术又迈进了一步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nanotheranostics
Nanotheranostics Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
10.40
自引率
0.00%
发文量
37
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信